BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Nektar Therapeutics Stock Surges 15% on Positive Clinical Trial Results
Nektar Therapeutics Stock Surges 15% on Positive Clinical Trial Results
13
3
BTCCSquare news:
Nektar Therapeutics (NKTR) saw its stock price jump over 15% following promising phase 2b trial data for its investigational drug rezpegaldesleukin. The clinical-stage biotech reported statistically significant improvements in moderate-to-severe atopic dermatitis, outperforming both placebo and the S&P 500's modest 0.5% gain.
The high-dose treatment demonstrated efficacy across primary and secondary endpoints, with sustained benefits observed in continuing participants. Safety profiles remained favorable, bolstering confidence in the drug's potential. Nektar is concurrently developing the same compound for alopecia areata, with clinical readouts expected in December.
By:
